- Home
- FUTU vs UTHR Comparison
FUTU vs UTHR Comparison
Compare FUTU & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FUTU | UTHR |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 20.4B |
| IPO Year | 2018 | 1999 |
Fundamental Metrics
Financial Performance| Metric | FUTU | UTHR |
|---|---|---|
| Price | $144.01 | $485.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $208.60 | ★ $520.00 |
| AVG Volume (30 Days) | ★ 1.5M | 358.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 27.86 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $85.76 | $8.56 |
| Revenue Next Year | $14.66 | $10.71 |
| P/E Ratio | ★ $17.05 | $17.57 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $70.60 | $266.98 |
| 52 Week High | $202.53 | $537.19 |
Technical Indicators
Market Signals| Indicator | FUTU | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 49.05 |
| Support Level | $142.33 | $463.64 |
| Resistance Level | $175.66 | $486.99 |
| Average True Range (ATR) | 5.02 | 18.81 |
| MACD | 0.03 | 0.70 |
| Stochastic Oscillator | 35.23 | 26.51 |
Price Performance
Historical ComparisonAbout FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and the United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services, and interest income.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.